Approved Drugs > FDA approves olaparib for germline BRCA-mutated metastatic breast cancer

Approved Drugs > FDA approves olaparib for germline BRCA-mutated metastatic breast cancer

FDA approves olaparib for germline BRCA-mutated metastatic breast cancer

• FDA granted regular approval to olaparib tablets (Lynparza, AstraZeneca Pharmaceuticals LP), a poly (ADP-ribose) polymerase (PARP) inhibitor, for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. More Information.  January 12, 2018